In a landmark phase II trial of women with stage III-IV or recurrent HER2 over-expressing uterine serous carcinomas, the addition of trastuzumab to carboplatin and paclitaxel as adjuvant treatment improved overall survival by over five months (HR 0.58; 95% [CI 0.34-0.99]) [26]. Here, ERBB2 is linked to serous adenocarcinoma.